Literature DB >> 8852585

Regional difference in induction of heme oxygenase-1 protein following rat transient forebrain ischemia.

A Takeda1, T Kimpara, H Onodera, Y Itoyama, S Shibahara, K Kogure.   

Abstract

Heme oxygenase (HO) is a rate-limiting enzyme in heme catabolism, the end products of which include iron, carbon monoxide and bilirubin. We investigated the changes in expression of an inducible form, heme oxygenase-1 (HO-1), and a constitutive form, HO-2, in rat brain following 20 min of forebrain ischemia, using specific antisera for HO-1 and HO-2. HO-1 protein was remarkably induced in brain following ischemia, while the level of HO-2 protein was not noticeably affected. The level of HO-1 protein expression was maximal at 12 h, which is in good agreement with the time course of the HO-1 mRNA induction. In the cortical mantle, most of the cells expressing increased HO-1 protein were identified as pyramidal neurons and astrocytes by their shapes and locations. In hippocampal CA-2 and CA-3 subfields, prominent induction was observed in astrocytes rather than in neuronal cells. By contrast, the HO-1 protein was not detected in the CA1 subfield following the insult, although the increased level of transcripts was evident in neurons and glial cells. These results suggest that not only in neuronal cells but also in astrocytes within the CA1 subfield, there may be an impairment of protein metabolism, preceding the delayed CA1 pyramidal cell losses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852585     DOI: 10.1016/0304-3940(96)12405-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors.

Authors:  M C Grabb; D W Choi
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

2.  Microglia regulate blood clearance in subarachnoid hemorrhage by heme oxygenase-1.

Authors:  Nils Schallner; Rambhau Pandit; Robert LeBlanc; Ajith J Thomas; Christopher S Ogilvy; Brian S Zuckerbraun; David Gallo; Leo E Otterbein; Khalid A Hanafy
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.